Study on Clinical Treatment of Brain Tumors
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 28 March 2025 | Viewed by 71
Special Issue Editor
Special Issue Information
Dear Colleagues,
In recent years, the development of antineoplastic agents has undergone significant changes, especially in the development of molecularly targeted agents. Drugs targeting driver mutations have shown remarkable efficacy, and in the clinical development of anti-tumor drugs for rare subtypes. The number of cases in which regulatory approval has been granted based on the primary efficacy endpoint of response rate in phase II trials is increasing. In addition, many pharmaceuticals are being introduced into clinical practice as genomic medicine, and it is expected that more drugs will be developed for tumors based on genetic abnormalities that are less common in the future.
However, brain tumors, especially malignant brain tumors such as glioblastoma, are still an area with a poor prognosis and high unmet medical needs, and the development of new treatment methods, including not only pharmaceuticals but also biotechnology products and medical devices, is sought after, and various clinical trials are being conducted. In this area, it is necessary not only to develop treatments, but also to create a consensus on efficacy endpoints for optimal response.
This Special Issue presents recent studies on the clinical treatment of brain tumors, working toward turning various brain tumors into prolonged overall survival.
Dr. Shinya Watanabe
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- brain tumors
- clinical treatment
- anti-tumor drugs
- clinical trials
